CA
ABBV icon

Crumly & Associates’s AbbVie ABBV Stock Holding History

Crumly & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.03M Buy
3,927
+1,102
+39% +$283K 0.18% 77
2026
Q2 		$711K Buy
2,825
+163
+6% +$35.1K 0.14% 93
2026
Q1 		$579K Buy
2,662
+405
+18% +$89.8K 0.12% 103
2025
Q4 		$516K Buy
2,257
+1,225
+119% +$279K 0.11% 108
2025
Q3 		$239K Buy
+1,032
New +$210K 0.05% 172
2020
Q3 		– Sell
-2,191
Closed -$215K – 62
2020
Q2 		$215K Buy
+2,191
New +$193K 0.2% 47

Other funds holding ABBV

HCM
Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Crumly & Associates's ABBV Position: Q3 2026 in Review

Crumly & Associates increased its AbbVie (ABBV) stake by 39% in Q3 2026, buying an estimated $283K and bringing the position to 3,927 shares worth $1.03M. The position accounts for 0.18% of the portfolio, ranked #77.

Crumly & Associates first reported a position in ABBV in Q2 2020 and has held it in 6 quarters since. 246 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Crumly & Associates held 3,927 shares of AbbVie worth $1.03M as of Q3 2026.
  • Crumly & Associates bought 1,102 AbbVie shares in Q3 2026, an estimated $283K.
  • AbbVie made up 0.18% of Crumly & Associates's portfolio in Q3 2026, its #77 holding.
  • Crumly & Associates first reported a position in AbbVie in Q2 2020 and has held it in 6 quarters since.
  • 246 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Crumly & Associates's 13F filing for Q3 2026, filed 7 Oct 2026.